Drug
HC-7366
HC-7366 is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Terminated(1)
Detailed Status
Recruiting3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
terminated125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_1
Phase I Study of HC-7366 for Acute Myeloid Leukemia
NCT06285890
recruitingphase_1
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
NCT07401875
recruitingphase_1
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT06234605
terminatedphase_1
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
NCT05121948
Clinical Trials (4)
Showing 4 of 4 trials
NCT06285890Phase 1
Phase I Study of HC-7366 for Acute Myeloid Leukemia
NCT07401875Phase 1
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
NCT06234605Phase 1
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT05121948Phase 1
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4